NOVO NORDISK A/S-B (NOV.DE) Fundamental Analysis & Valuation

FRA:NOV • DK0062498333

Current stock price

32.02 EUR
-0.27 (-0.85%)
Last:

This NOV.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. NOV.DE Profitability Analysis

1.1 Basic Checks

  • In the past year NOV was profitable.
  • In the past year NOV had a positive cash flow from operations.
  • Each year in the past 5 years NOV has been profitable.
  • NOV had a positive operating cash flow in each of the past 5 years.
NOV.DE Yearly Net Income VS EBIT VS OCF VS FCFNOV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 18.87%, NOV belongs to the top of the industry, outperforming 98.08% of the companies in the same industry.
  • NOV has a better Return On Equity (52.79%) than 92.31% of its industry peers.
  • With an excellent Return On Invested Capital value of 30.79%, NOV belongs to the best of the industry, outperforming 94.23% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for NOV is significantly above the industry average of 14.90%.
  • The 3 year average ROIC (43.61%) for NOV is well above the current ROIC(30.79%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 18.87%
ROE 52.79%
ROIC 30.79%
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
NOV.DE Yearly ROA, ROE, ROICNOV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • With an excellent Profit Margin value of 33.14%, NOV belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • In the last couple of years the Profit Margin of NOV has remained more or less at the same level.
  • NOV has a better Operating Margin (41.30%) than 94.23% of its industry peers.
  • In the last couple of years the Operating Margin of NOV has remained more or less at the same level.
  • NOV has a Gross Margin of 80.98%. This is amongst the best in the industry. NOV outperforms 84.62% of its industry peers.
  • NOV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 41.3%
PM (TTM) 33.14%
GM 80.98%
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
NOV.DE Yearly Profit, Operating, Gross MarginsNOV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

3

2. NOV.DE Health Analysis

2.1 Basic Checks

  • NOV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • NOV has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NOV has been increased compared to 5 years ago.
  • The debt/assets ratio for NOV is higher compared to a year ago.
NOV.DE Yearly Shares OutstandingNOV.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B
NOV.DE Yearly Total Debt VS Total AssetsNOV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100B 200B 300B 400B 500B

2.2 Solvency

  • NOV has an Altman-Z score of 3.59. This indicates that NOV is financially healthy and has little risk of bankruptcy at the moment.
  • With a Altman-Z score value of 3.59, NOV perfoms like the industry average, outperforming 55.77% of the companies in the same industry.
  • The Debt to FCF ratio of NOV is 4.52, which is a neutral value as it means it would take NOV, 4.52 years of fcf income to pay off all of its debts.
  • NOV has a Debt to FCF ratio of 4.52. This is comparable to the rest of the industry: NOV outperforms 55.77% of its industry peers.
  • A Debt/Equity ratio of 0.61 indicates that NOV is somewhat dependend on debt financing.
  • NOV has a Debt to Equity ratio of 0.61. This is comparable to the rest of the industry: NOV outperforms 51.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 4.52
Altman-Z 3.59
ROIC/WACC4.46
WACC6.9%
NOV.DE Yearly LT Debt VS Equity VS FCFNOV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.3 Liquidity

  • NOV has a Current Ratio of 0.80. This is a bad value and indicates that NOV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NOV has a Current ratio of 0.80. This is amonst the worse of the industry: NOV underperforms 86.54% of its industry peers.
  • A Quick Ratio of 0.57 indicates that NOV may have some problems paying its short term obligations.
  • The Quick ratio of NOV (0.57) is worse than 86.54% of its industry peers.
Industry RankSector Rank
Current Ratio 0.8
Quick Ratio 0.57
NOV.DE Yearly Current Assets VS Current LiabilitesNOV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B 200B

4

3. NOV.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 1.77% over the past year.
  • The Earnings Per Share has been growing by 20.66% on average over the past years. This is a very strong growth
  • Looking at the last year, NOV shows a small growth in Revenue. The Revenue has grown by 6.43% in the last year.
  • NOV shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.48% yearly.
EPS 1Y (TTM)1.77%
EPS 3Y23.52%
EPS 5Y20.66%
EPS Q2Q%-4.73%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-7.63%

3.2 Future

  • The Earnings Per Share is expected to grow by 5.80% on average over the next years.
  • Based on estimates for the next years, NOV will show a small growth in Revenue. The Revenue will grow by 4.07% on average per year.
EPS Next Y-3.96%
EPS Next 2Y-2.8%
EPS Next 3Y1.16%
EPS Next 5Y5.8%
Revenue Next Year-4.65%
Revenue Next 2Y-0.75%
Revenue Next 3Y1.62%
Revenue Next 5Y4.07%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NOV.DE Yearly Revenue VS EstimatesNOV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100B 200B 300B
NOV.DE Yearly EPS VS EstimatesNOV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

6

4. NOV.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 10.40, the valuation of NOV can be described as very reasonable.
  • 82.69% of the companies in the same industry are more expensive than NOV, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 25.79. NOV is valued rather cheaply when compared to this.
  • Based on the Price/Forward Earnings ratio of 10.82, the valuation of NOV can be described as reasonable.
  • Based on the Price/Forward Earnings ratio, NOV is valued cheaper than 80.77% of the companies in the same industry.
  • NOV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.80.
Industry RankSector Rank
PE 10.4
Fwd PE 10.82
NOV.DE Price Earnings VS Forward Price EarningsNOV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NOV indicates a rather cheap valuation: NOV is cheaper than 82.69% of the companies listed in the same industry.
  • NOV's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 36.7
EV/EBITDA 7.86
NOV.DE Per share dataNOV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • The excellent profitability rating of NOV may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.5
EPS Next 2Y-2.8%
EPS Next 3Y1.16%

7

5. NOV.DE Dividend Analysis

5.1 Amount

  • NOV has a Yearly Dividend Yield of 4.74%, which is a nice return.
  • In the last 3 months the price of NOV has falen by -22.04%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • NOV's Dividend Yield is rather good when compared to the industry average which is at 1.92. NOV pays more dividend than 86.54% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.91, NOV pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.74%

5.2 History

  • The dividend of NOV is nicely growing with an annual growth rate of 19.05%!
Dividend Growth(5Y)19.05%
Div Incr Years0
Div Non Decr Years0
NOV.DE Yearly Dividends per shareNOV.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 2026 2 4 6 8 10

5.3 Sustainability

  • 50.53% of the earnings are spent on dividend by NOV. This is a bit on the high side, but may be sustainable.
  • NOV's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP50.53%
EPS Next 2Y-2.8%
EPS Next 3Y1.16%
NOV.DE Yearly Income VS Free CF VS DividendNOV.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B
NOV.DE Dividend Payout.NOV.DE Dividend Payout, showing the Payout Ratio.NOV.DE Dividend Payout.PayoutRetained Earnings

NOV.DE Fundamentals: All Metrics, Ratios and Statistics

NOVO NORDISK A/S-B

FRA:NOV (3/19/2026, 10:20:41 AM)

32.02

-0.27 (-0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-03
Earnings (Next)05-06
Inst Owners32.22%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap142.38B
Revenue(TTM)309.06B
Net Income(TTM)102.43B
Analysts69.41
Price Target49.38 (54.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.74%
Yearly Dividend1.56
Dividend Growth(5Y)19.05%
DP50.53%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.82%
Min EPS beat(2)-7.04%
Max EPS beat(2)1.39%
EPS beat(4)2
Avg EPS beat(4)-0.71%
Min EPS beat(4)-7.04%
Max EPS beat(4)3.94%
EPS beat(8)5
Avg EPS beat(8)1.01%
EPS beat(12)8
Avg EPS beat(12)1.47%
EPS beat(16)11
Avg EPS beat(16)1.68%
Revenue beat(2)1
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)1.07%
Revenue beat(4)1
Avg Revenue beat(4)-0.92%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)1.07%
Revenue beat(8)3
Avg Revenue beat(8)0.15%
Revenue beat(12)6
Avg Revenue beat(12)0.52%
Revenue beat(16)9
Avg Revenue beat(16)0.84%
PT rev (1m)-8.63%
PT rev (3m)-11.78%
EPS NQ rev (1m)12.35%
EPS NQ rev (3m)0.79%
EPS NY rev (1m)-2.9%
EPS NY rev (3m)-7.38%
Revenue NQ rev (1m)1.33%
Revenue NQ rev (3m)-50.96%
Revenue NY rev (1m)-4.89%
Revenue NY rev (3m)-6.85%
Valuation
Industry RankSector Rank
PE 10.4
Fwd PE 10.82
P/S 3.44
P/FCF 36.7
P/OCF 8.93
P/B 5.48
P/tB 16.62
EV/EBITDA 7.86
EPS(TTM)3.08
EY9.62%
EPS(NY)2.96
Fwd EY9.24%
FCF(TTM)0.87
FCFY2.72%
OCF(TTM)3.58
OCFY11.19%
SpS9.3
BVpS5.84
TBVpS1.93
PEG (NY)N/A
PEG (5Y)0.5
Graham Number20.12
Profitability
Industry RankSector Rank
ROA 18.87%
ROE 52.79%
ROCE 39.01%
ROIC 30.79%
ROICexc 33.56%
ROICexgc 59.2%
OM 41.3%
PM (TTM) 33.14%
GM 80.98%
FCFM 9.38%
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
ROICexc(3y)50.94%
ROICexc(5y)53.03%
ROICexgc(3y)100.46%
ROICexgc(5y)105.49%
ROCE(3y)55.75%
ROCE(5y)58.53%
ROICexgc growth 3Y-22.89%
ROICexgc growth 5Y-7.78%
ROICexc growth 3Y-18.13%
ROICexc growth 5Y-11.63%
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
F-Score5
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 4.52
Debt/EBITDA 0.79
Cap/Depr 409.94%
Cap/Sales 29.16%
Interest Coverage 37.34
Cash Conversion 79.59%
Profit Quality 28.3%
Current Ratio 0.8
Quick Ratio 0.57
Altman-Z 3.59
F-Score5
WACC6.9%
ROIC/WACC4.46
Cap/Depr(3y)363.9%
Cap/Depr(5y)282.93%
Cap/Sales(3y)21.19%
Cap/Sales(5y)15.43%
Profit Quality(3y)60.31%
Profit Quality(5y)79.23%
High Growth Momentum
Growth
EPS 1Y (TTM)1.77%
EPS 3Y23.52%
EPS 5Y20.66%
EPS Q2Q%-4.73%
EPS Next Y-3.96%
EPS Next 2Y-2.8%
EPS Next 3Y1.16%
EPS Next 5Y5.8%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-7.63%
Revenue Next Year-4.65%
Revenue Next 2Y-0.75%
Revenue Next 3Y1.62%
Revenue Next 5Y4.07%
EBIT growth 1Y-4.76%
EBIT growth 3Y19.04%
EBIT growth 5Y18.51%
EBIT Next Year8.51%
EBIT Next 3Y5.92%
EBIT Next 5Y7.75%
FCF growth 1Y-58.38%
FCF growth 3Y-23.26%
FCF growth 5Y-0.6%
OCF growth 1Y-1.54%
OCF growth 3Y14.72%
OCF growth 5Y18.05%

NOVO NORDISK A/S-B / NOV.DE Fundamental Analysis FAQ

What is the fundamental rating for NOV stock?

ChartMill assigns a fundamental rating of 6 / 10 to NOV.DE.


Can you provide the valuation status for NOVO NORDISK A/S-B?

ChartMill assigns a valuation rating of 6 / 10 to NOVO NORDISK A/S-B (NOV.DE). This can be considered as Fairly Valued.


What is the profitability of NOV stock?

NOVO NORDISK A/S-B (NOV.DE) has a profitability rating of 9 / 10.


Can you provide the expected EPS growth for NOV stock?

The Earnings per Share (EPS) of NOVO NORDISK A/S-B (NOV.DE) is expected to decline by -3.96% in the next year.


Is the dividend of NOVO NORDISK A/S-B sustainable?

The dividend rating of NOVO NORDISK A/S-B (NOV.DE) is 7 / 10 and the dividend payout ratio is 50.53%.